核酸适配体分子探针在肿瘤诊断和治疗中的研究进展

doi:10.3760/cma.j.issn.1673422X.2016.07.009

摘要/Abstract

摘要： 核酸适配体是用配体指数富集法进化系统(SELEX)技术在体外合成筛选所得的单链寡核苷酸，通过折叠成独特的空间结构特异性识别结合靶标分子。核酸适配体功能上类似于抗体，但与靶向目标的特异结合优于抗体，被作为新型分子探针用于肿瘤检测与治疗领域。

关键词: 肿瘤, 适体, 核苷, 分子诊断技术, 治疗

Abstract: ucleic acid aptamer is the systematic evolution of ligands by exponential enrichment synthesized in vitro screening technology resulting singlestranded oligonucleotides (DNA or RNA), by folding into unique spatial structure specific recognition binding target molecules. Aptamers function is similar to the antibodies but more specifically, as novel molecular probes for the field of cancer therapeutics and diagnostics.

Key words: Neoplasms, Aptamers, nucleotide, Molecular diagnostic techniques, Therapy

梁剑伟, 颜汝平, 王剑松. 核酸适配体分子探针在肿瘤诊断和治疗中的研究进展[J]. 国际肿瘤学杂志, 2016, 43(7): 519-522.

LIANG Jian-Wei, YAN Ru-Ping, WANG Jian-Song. Nucleic acid aptamer for caner therapeutics and diagnostics[J]. Journal of International Oncology, 2016, 43(7): 519-522.

参考文献

［1］ Fang X, Tan W. Aptamers generated from cellSELEX for molecular medicine: a chemical biology approach［J］. Acc Chem Res, 2010, 43(1): 4857. DOI: 10.1021/ar900101s. ［2］ Chen A, Yang S. Replacing antibodies with aptamers in lateral flow immunoassay［J］. Biosens Bioelectron, 2015, 71: 230242. DOI: 10.1016/j.bios.2015.04.041. ［3］ Nimjee SM, Rusconi CP, Sullenger BA. Aptamers: an emerging class of therapeutics［J］. Annu Rev Med, 2005, 56: 555583. DOI: 10.1146/annurev.med.56.062904.144915. ［4］ Darmostuk M, Rimpelova S, Gbelcova H, et al. Current approaches in SELEX: an update to aptamer selection technology［J］. Biotechnol Adv, 2015, 33(6 Pt 2): 11411161. DOI: 10.1016/j.biotechadv.2015.02.008. ［5］ Ye M, Hu J, Peng M, et al. Generating aptamers by cellSELEX for applications in molecular medicine［J］. Int J Mol Sci, 2012, 13(3): 33413353. DOI: 10.3390/ijms13033341. ［6］ Cao HY, Yuan AH, Chen W, et al. A DNA aptamer with high affinity and specificity for molecular recognition and targeting therapy of gastric cancer［J］. BMC Cancer, 2014, 14: 699. DOI: 10.1186/1471240714699. ［7］ Shi H, He X, Wang K, et al. Activatable aptamer probe for contrastenhanced in vivo cancer imaging based on cell membrane proteintriggered conformation alteration［J］. Proc Natl Acad Sci USA, 2011, 108(10): 39003905. DOI: 10.1073/pnas.1016197108. ［8］ Cai S, Li G, Zhang X, et al. A signalon fluorescent aptasensor based on singlestranded DNAsensitized luminescence of Terbium (Ⅲ) for labelfree detection of breast cancer cells［J］. Talanta, 2015, 138: 225230. DOI: 10.1016/j.talanta.2015.02.056. ［9］ Ai J, Xu Y, Lou B, et al. Multifunctional AS1411functionalized fluorescent Gold nanoparticles for targeted cancer cell imaging and efficient photodynamic therapy［J］. Talanta, 2014, 118: 5460. DOI: 10.1016/j.talanta.2013.09.062. ［10］ Zhu Y, Chandra P, Shim YB. Ultrasensitive and selective electrochemical diagnosis of breast cancer based on a hydrazineAu nanoparticleaptamer bioconjugate［J］. Anal Chem, 2013, 85(2): 10581064. DOI: 10.1021/ac302923k. ［11］ Kong RM, Ding L, Wang Z, et al. A novel aptamerfunctionalized MoS2 nanosheet fluorescent biosensor for sensitive detection of prostate specific antigen［J］. Anal Bioanal Chem, 2015, 407(2): 369377. DOI: 10.1007/s0021601482679. ［12］ Lee J, Kang HJ, Jang H, et al. Simultaneous imaging of two different cancer biomarkers using aptamerconjugated quantum dots［J］. Sensors (Basel), 2015, 15(4): 85958604. DOI: 10.3390/s150408595. ［13］ Hwang do W, Ko HY, Lee JH, et al. A nucleolintargeted multimodal nanoparticle imaging probe for tracking cancer cells using an aptamer［J］. J Nucl Med, 2010, 51(1): 98105. DOI: 10.2967/jnumed.109.069880. ［14］ Zhou J, Rossi JJ. Cellspecific aptamermediated targeted drug delivery［J］. Oligonucleotides, 2011, 21(1): 110. DOI: 10.1089/oli.2010.0264. ［15］ Li N, Nguyen HH, Byrom M, et al. Inhibition of cell proliferation by an antiEGFR aptamer［J］. PLoS One, 2011, 6(6): e20299. DOI: 10.1371/journal.pone.0020299. ［16］ Dassie JP, Hernandez LI, Thomas GS, et al. Targeted inhibition of prostate cancer metastases with an RNA aptamer to prostatespecific membrane antigen［J］. Mol Ther, 2014, 22(11): 19101922. DOI: 10.1038/mt.2014.117. ［17］ Zamay TN, Kolovskaya OS, Glazyrin YE, et al. DNAaptamer targeting vimentin for tumor therapy in vivo［J］. Nucleic Acid Ther, 2014, 24(2): 160170. DOI: 10.1089/nat.2013.0471. ［18］ Xiang D, Shigdar S, Qiao G, et al. Nucleic acid aptamerguided cancer therapeutics and diagnostics: the next Generation of cancer medicine［J］. Theranostics, 2015, 5(1): 2342. DOI: 10.7150/thno.10202. ［19］ Xing H, Tang L, Yang X, et al. Selective delivery of an anticancer drug with aptamerfunctionalized liposomes to breast cancer cells in vitro and in vivo［J］. J Mater Chem B Mater Biol Med, 2013, 1(39): 52885297. DOI: 10.1039/C3TB20412J. ［20］ Zhou C, Chen T, Wu C, et al. Aptamer CaCO3 nanostructures: a facile, pHresponsive, specific platform for targeted anticancer theranostics［J］. Chem Asian J, 2015, 10(1): 166171. DOI: 10.1002/asia.201403115. ［21］ Wang K, Yao H, Meng Y, et al. Specific aptamerconjugated mesoporous silicacarbon nanoparticles for HER2targeted chemophotothermal combined therapy［J］. Acta Biomater, 2015, 16: 196205. DOI: DOI: 10.1016/j.actbio.2015.01.002. ［22］ Thiel KW, Hernandez LI, Dassie JP, et al. Delivery of chemosensitizing siRNAs to HER2+breast cancer cells using RNA aptamers［J］. Nucleic Acids Res, 2012, 40(13): 63196337. DOI: 10.1093/nar/gks294. ［23］ Lai WY, Wang WY, Chang YC, et al. Synergistic inhibition of lung cancer cell invasion, tumor growth and angiogenesis using aptamersiRNA chimeras［J］. Biomaterials, 2014, 35(9): 29052914. DOI: 10.1016/j.biomaterials.2013.12.054. ［24］ Dai F, Zhang Y, Zhu X, et al. Anticancer role of MUC1 aptamermiR29b chimera in epithelial ovarian carcinoma cells through regulation of PTEN methylation［J］. Target Oncol, 2012, 7(4): 217225. DOI: 10.1007/s1152301202367.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[3]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[4]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[5]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[6]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[7]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[8]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[9]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[10]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[11]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[12]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[13]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[14]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[15]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.